The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
November 19th 2024
The FDA granted fast track designation to ALE.P02 for CLDN1-positive squamous solid tumors.
November 15th 2024
Channeling His Creativity Into Oncology: A "Renaissance Man" Makes a Mark in Lymphoma Research
December 8th 2011Andre Goy, MD, MS, treats lymphoma patients at New Jersey's largest cancer center, Goy, 54, is also a translational researcher widely known for his work showing the first-ever evidence of activity of bortezomib.
University of Pennsylvania's Abramson Cancer Center: Leaders in Groundbreaking Therapies
Established in 1973 as the University of Pennsylvania's Cancer Center and subsequently renamed in 2002, the Abramson Cancer Center is a world leader in research, patient care, and education.
The Cleveland Clinic's Taussig Cancer Institute: Patient Experience Reigns Supreme
The Cleveland Clinic has long been at the forefront of cutting-edge medicine and research. The center's reputation as a world leader in a multitude of fields, including oncology, is undisputed.